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Abstract
Background: The accurate estimation of outcome in patients with malignant disease is an essential component of
the optimal treatment, decision-making and patient counseling processes. The prognosis and disease outcome of
breast cancer patients can differ according to geographic and ethnic factors. To our knowledge, to date these
factors have never been validated in a homogenous loco-regional patient population, with the aim of achieving
accurate predictions of outcome for individual patients. To clarify this topic, we created a new comprehensive
prognostic and predictive model for Taiwanese breast cancer patients based on a range of patient-related and
various clinical and pathological-related variables.
Methods: Demographic, clinical, and pathological data were analyzed from 1 137 patients with breast cancer who
underwent surgical intervention. A survival prediction model was used to allow analysis of the optimal
combination of variables.
Results: The area under the receiver operating characteristic (ROC) curve, as applied to an independent validation
data set, was used as the measure of accuracy. Results were compared by comparing the area under the ROC
curve.
Conclusions: our model building exercise of mortality risk was able to predict disease outcome for individual
patients with breast cancer. This model could represent a highly accurate prognostic tool for Taiwanese breast
cancer patients.
Background
Breast cancer is a serious threat to women’sh e a l t h .I n
Taiwan, breast cancer ranked fourth among the top 10
causes of death among women in the period from 1995
to 2003 [1]. The investigative results published by the
Bureau of Health Promotion, Department of Health,
Taiwan, indicate that the incidence and mortality of
breast cancer increase almost every year. The incidence
rate and the age-adjusted incidence rate have both
i n c r e a s e da l m o s tt w o - f o l dw h e nc o m p a r e dw i t ht h o s e
calculated for the period from 1995 to 2003. The corre-
sponding mortality also increased: the mortality rate
increased from 8.9 per 10000 people to 12.45 per 10000
people and the age-adjusted death rate increased from
8.79 per 10000 people to 11.07 per 10000 people [2].
Improved surgical procedures and chemotherapy regi-
mens seem not to have effectively diminished breast
cancer incidence and mortality [3,4]. It is therefore
important to identify risk factors that significantly affect
survival among women with breast cancer, as the con-
trol of these risk factors.
Unlike most countries in Asia, which have produced
few publications on cancer recurrence risk analyses
among breast cancer patients, many such studies have
been published in Western countries [5-8]. Among
them, meta-analyses are widely used to discuss causal
relationships between risk factors and breast cancer sur-
vival [9,10]. Meta-analyses are secondary analyses that
derive results from data reported in different studies
addressing similar research topics. A different combina-
tion of methods can lead to different meta-analytical
outcomes. Furthermore, it is extremely difficult to pre-
dict the disease outcome of cancer patients. To solve
this problem, we used a logistic regression approach to
simultaneously investigate the relationships between all
significantly effected risk factors, including demographic, * Correspondence: ylkuo@mail.ncku.edu.tw
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breast cancer patients.
Methods
The original data was collected from 1 190 patients with
breast cancer diagnosed between January 1, 1995 and
August 31, 2005 at the National Cheng Kung University
Hospital, Tainan, Taiwan. As our objective was to study
the prognostic factors of breast cancer and to develop
more precise predictive mortality risk models, both
patients with stage IV disease and patients who were
followed up for less than one year were excluded from
our analyses. Among the remaining 1 137 patients,
70 died and the other 1 067 were censored. The median
age of the patients was 49 years (range, 20-88 years).
Ethical approval was provided by Human Experiment
and Ethics committee of the National Cheng Kung
University Hospital (ER-99-076).
A variety of potential breast cancer risk factors were
constructed for each patient. The demographic data
included marriage status, education level, familial history
of breast cancer, presence of other underlying diseases,
and menopause status. The clinical data included physi-
cal examination (PE), ultrasound (US), fine-needle
aspiration cytology (FNAC), core needle biopsy (CNB),
mammography, type of breast surgery, and type of axil-
lary lymphatic surgery. Finally, the pathological findings
included tumor size, nodal status, tumor grade, estrogen
receptor (ER) status, progesterone receptor (PR) status,
Her-2/neu status, extensive intraductal carcinoma (EIC),
presence of lymphatic tumor emboli (LTE), hepatitis B
and C status, and hepatitis B surface antigen (HBsAg)
and hepatitis C virus antibody (HCV Ab). The clinical
and pathological data were classified into four cate-
g o r i e s :b e n i g n( B ) ,i n t e r m e d i ate (I), suspicious (S), and
malignant (M). The different treatment modalities,
including anti hormone therapy, radiotherapy, and
chemotherapy, were also included in our analysis.
Statistical methods
The overall survival function for breast cancer patients
was calculated using the Kaplan-Meier method: the log-
rank test was used to test the significance of different
stage groups [11]. To investigate the association between
survival status and each potential risk factor, odds ratios
were computed and p values were evaluated by using
univariate logistic regression test, where applicable [12].
Odds ratios were used to evaluate the relative odds of
death caused by breast cancer between two groups
sorted under a risk factor, and p values were calculated
to assess significance of results. A multivariable logistic
regression analysis was used to measure the significance
of several risk factors simultaneously and to predict
the survival probability of breast cancer patients [12].
To determine the accuracy of our model, Bootstrap
method was used, which can be implemented by obtain-
ing a number of re-samples of our observed dataset
[13]. The predictive model, which was built using for-
ward stepwise analyses, included only the risk factors
that showed significance in the univariate analyses. Sta-
tistical significance was set at p < 0.05.
Three methods were used for the evaluation of the fit-
ness of the multivariable logistic regression model. First,
ROC curves (using FORTRAN programs) [14] were
plotted to estimate the sensitivity and specificity of the
predictive model. The closer that the area under ROC
curve is to 1, the better the fit of the model. Second, the
Hosmer-Lemeshow test, written as C\and=∑k=1gn\pri-
mek(pk−p\andk)2p\andk(1−p\andk) for the statistic
being tested (where n\primek is the number of patients
in the k
th group, and p\andk and pk are the predicted
and real possibilities of death, respectively, in the k
th
group) was used to examine the fitness of the predictive
model by considering the difference between the pre-
dicted and observed probabilities of death caused by
breast cancer. Patients were divided into several groups
according to ordered predicted probability of death. The
statistic Ĉ is well approximated by the chi-square distri-
bution with g-2 degrees of freedom, X
2
g-2.T h el a r g e r
the p value obtained using the Hosmer-Lemeshow test,
(which corresponds to a smaller Ĉ), the smaller the
square of the distance between p\andk and pk,a n d
hence, the better the fit of the model [15,16]. The com-
parison was performed based on the confidence interval
of both models using the SPSS software, version 11.
Results
The overall median duration of patient follow-up was
60.3 months (range, 11.93-150.3 months). According to
the staging rules of practice guidelines in oncology from
the National Comprehensive Cancer Network, 70
patients (6.2%) patients had stage 0 disease, 310 patients
(27.2%) had stage I disease, 506 patients (44.5%) had
stage II disease, and 251 patients (22.1%) had stage III
disease. The median duration of patient follow-up was
similar for each stage (close to five years), with the
exception of stage 0. The five-year survival probability
for breast cancer was greater than 90%, and even for
patients with stage III disease, the survival probability
for five years was 84.33%. Log-rank testing showed that
the differences in survival at the different stages were
significant (p < 0.0001) (Figure 1).
Associations of breast cancer mortality with
demographic, clinical, and pathological factors
Patients for whom risk factor values were missing were
excluded from the analytical process. Among the demo-
graphic data, only age and menopause correlated
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was lowest for patients between the ages of 36 and
57 years (4.5%). Conversely, patients aged from 20 to
35 years had the highest mortality (12%). The mortality
difference for these two age groups was significant (p =
0.002). Regarding the menopausal status, the mortality
of postmenopausal patients was higher than that of pre-
menopausal patients, or of patients who had hysterect-
omy or oophorectomy (p = 0.0082); however, the effect
of the menopause status on breast cancer mortality
could be a reflection of the age of the patients. (Table 1)
The analysis of the clinical data revealed that all clinical
risk factors were correlated with survival status. (Table
2) In what concerns the pathology data, the survival rate
did not correlate with hepatitis status, HBsAg, or HCV
Ab. In contrast, the following pathology outcomes were
positively associated with increased breast cancer mor-
tality: higher tumor grade (p < 0.0001), negative ER sta-
tus (p = 0.0086), negative PR status (p = 0.0086),
positive Her-2/Neu status (p = 0.0137), absence of EIC
(p = 0.0323), presence of LTE (p = 0.0004), increased
tumor size (p < 0.0001), axillary lymph nodes (p <
0.0001), and abandonment or refusal of chemotherapy
treatment (p < 0.0001) (Table 3).
Multivariable logistic regression
Of the original 1 067 patients, 818 patients with complete
data were included in the multivariable logistic regression
analysis. Among them, 43 patients died and 775 were cen-
sored. As shown in Table 4, the odds ratio for patients
aged 36-60 years versus patients aged 20-35 years is 0.254,
which means that the odds of death for a patient in the
latter age group is approximately four times (1/0.254)
greater than that for patients in the former age group (p =
0.0029). The odds ratio of patients with an ultrasound
examination showing malignancy were also around two
times higher than those with benign, intermediate, or sus-
picious ultrasound results (odds ratio = 2.028, p < 0.0001).
In what concerns the remaining four chosen pathological
risk factors, the odds of death were positively correlated
with a higher tumor grade (odds ratio = 1.626, p = 0.01)
or lymph node involvement (odds ratio = 3.054, p <
0.0001): the odds increased about two times when the
tumor grade was II versus grade I, or grade II versus grade
III, and three times when lymph node status was N1 or
N2 versus N0 or N3 versus N1 or N2. Patients who aban-
doned or refused chemotherapy had approximately three
times greater odds of death than patients who completed
chemotherapy treatment (odds ratio = 0.242, p = 0.0016).
Compared to the univariate logistic analysis, multivariable
logistic analysis and Bootstrap for variables showed only
Figure 1 The Kaplan-Meier survival curve in each stage of the
patients.
Table 1 Description of the population by univariate
logistic regression test using the demographic data
Demographic Data
Factor Death(%) Odds Ratio P
Marital status 1.334 N.S.
Married (n = 1071) 67 (6.3%)
Unmarried (n = 63) 3 (4.8%)
Education level 1.677 0.057
Below junior high school
(n = 685)
50 (7.3%)
Above senior high school
(n = 446)
20 (4.5%)
Menopause 1.925 0.008 *
Premenopause (n = 397) 35 (8.8%)
Others (n = 732) 35 (4.8%)
Hormone use 1.319 N.S.
No (n = 798) 40 (5.0%)
Yes (n = 104) 4 (3.8%)
Familial breast cancer history 0.732 N.S.
No (n = 997) 59 (5.9%)
Yes (n = 139) 11 (7.9%)
Underlying diseases 0.713 N.S.
No (n = 577) 30 (5.2%)
Yes (n = 560) 40 (7.1%)
Age (years) 0.378 (a v.s. c) 0.002 *
0.745 (b v.s. c) N.S.
36-60 (a) (n = 856) 42 (4.9%)
61-85 (b) (n = 206) 19 (9.2%)
20-35 (c) (n = 75) 9 (12%)
Menopause: others, excluding premenopase, hysterectomy, and s/p ovarian.
Age: others, concluding patients more than 58 or less than 36.
N. S.: Statistically not significant
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(p = < 0.0001, <0.0001 and 0.111 respectively).
Goodness of fit
Our model showed a good fit based on both the ROC
curve and the Hosmer-Lemeshow test. The area under
the ROC curve was 0.894 with asymmetric confidence
interval equals (0.8405, 0.9318), not concluding 0.5. The
larger area, farther from 0.5 and closer to 1, showed the
excellence of the model’s performance. Best cutoff value
showed p = 0.0419, sensitivity = 0.86, specificity = 0.756,
positive predictive value (PPV) = 0.1889 and negative
predictive value (NPV) = 0.9879 (Figure 2). The Hos-
mer-Lemeshow test also showed excellent performance
of the model (p = 0.9448) (Figure 3). The curve of the
observed probability of death is much closer to that of
the predicted probability of death.
Discussion
In recent years, several improvements in medical treat-
ment modalities in breast cancer were observed;
Table 2 Description of the population by univariate
logistic regression test using the clinical data
Clinical Data
Factor Mortality(%) Odds Ratio P-value
Physical examination 0.304 (a v.s. c) 0.002 *
0.616 (b v.s. c) N.S.
N, B, I (a) (n = 484) 16 (3.3%)
S (b) (n = 216) 14 (6.5%)
M (c) (n = 267) 27 (10.1%)
Ultrasound 0.279 <.0001 *
N, B, I, S (n = 741) 27 (3.6%)
M (n = 251) 30 (12%)
FNAC 0.375 0.009*
B, I, S (n = 323) 9 (2.8%)
M (n = 591) 42 (7.1%)
Mammography 0.269 0.0001 *
BR1-4 (n = 446) 11 (2.5%)
BR5 (n = 512) 44 (8.6%)
Diagnostic
method
0.429 0.0008 *
Core biopsy (n = 661) 27 (4.1%)
Others (n = 476) 43 (9.0%)
Breast surgery 0.063 0.0001 *
BCS (n = 341) 2 (0.6%)
TM (n = 795) 68 (8.6%)
Lymphatic surgery 0.237 0.0004 *
SLNB (n = 341) 7 (2.1%)
ALND (n = 775) 63 (8.1%)
Diagnostic: others, concluding combined methods, Excision biopsy, and FS
N. S.: Statistically not significant
Table 3 Description of the population by univariate
logistic regression test using the pathological data
Pathological Data
Risk factors Mortality
(%)
Odds Ratio P-value
Pathological report <.001 (a v.s. c) N.S.
0.532 (b v.s. c) N.S.
Others (a) (n = 138) 0
Invasive ductal carcinoma
(b) (n = 966)
66 (6.8%)
Invasive lobular carcinoma
(c) (n = 33)
4 (12.1%)
Tumor grade 2.172 <.0001 *
III (n = 234) 27
(11.5%)
II (n = 431) 24 (5.6%)
I (n = 294) 8 (2.7%)
ER/PR 1.99 0.009 *
(-, -), (-, +), (+, -) (n = 583) 47 (8.1%)
(+, +) (n = 545) 23 (4.2%)
Her-2/Neu 2.125 0.014*
+++ (n = 181) 18 (9.9%)
-, +, ++ (n = 668) 33 (4.9%)
EIC 2.036 0.032 *
Absent (n = 590) 46 (7.8%)
Present (n = 301) 12 (4.0%)
LTE 2.856 0.0004 *
Present (n = 501) 46 (9.2%)
Absent (n = 468) 16 (3.4%)
HBsAg 1.22 N.S.
+ (n = 124) 8 (6.5%)
- (n = 598) 32 (5.4%)
HCVAb 1.103 N.S.
+ (n = 50) 3 (6%)
- (n = 658) 36 (5.5%)
R/T 1.002 N.S.
Yes (n = 581) 39 (6.7%)
No (n = 552) 31 (5.6%)
Anti-hormone therapy 1.002 N.S.
No (n = 228) 14 (6.2%)
Yes (n = 909) 56 (6.2%)
Tumor size 2.579 <.0001 *
T4 (n = 57) 10
(17.5%)
T2 or T3 (n = 595) 45 (7.6%)
Tis or T1 (n = 485) 15 (3.1%)
Node 4.053 <.0001 *
N3 (n = 81) 23
(28.4%)
N1 or N2 (n = 377) 31 (8.2%)
N0 (n = 677) 16 (2.4%)
Chemotherapy 0.061 (a v.s. c) <0.0001*
0.391 (b v.s. c) 0.009 *
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values for breast cancer patients remains ambiguous
[5,6]. It is important to improve the efficiency of pre-
dicting the survival of breast cancer patients; therefore,
a model building exercise can be extended to include
any number of prognostic or risk factors, while also pro-
viding treatment predictions. The TNM classification
system has long been the accepted predictive tool for
breast cancer and provides useful information for the
Table 4 Comparison of risk factors calculated using the univariate logistic analysis, multivariable logistic analysis and
Bootstrap for variables
Univariate logistic analysis Multivariate logistic analysis Bootstrap for Variables in the
Equation
Factors Odds Ratio 95% CI P-value Odds Ratio 95% CI P-value Std.
Error
95% CI P-value
Age (years)
36-60 (a) 2.646 (c v.s. a) (1.232, 5.650) 0.002 3.937 (c v.s. a) (1.403,
11.111)
0.003 0.892 (0.945, 12.195) 0.013
61-85 (b) 1.342 (c.v.s. b) (0.579, 3.115) 1.548 (c v.s. b) (0.492, 4.878) 0.924 (0.370, 5.348)
20-35 (c)
Ultrasound
M 3.584 (2.088, 6.173) <0.0001 1.977 (1.545, 4.367) <0.0001 0.471 (1.023, 4.993) 0.111
N, B, I, S
Mammography
BR5 3.717 (1.898, 7.299) 0.0001 3.058 (1.049, 8.929) 0.048 1.315 (1.121, 1.530) 0.028
BR1-4
Diagnostic
method
Others 2.331 (1.422, 3.846) 0.001 2.519 (1.172, 5.410) 0.028 0.427 (1.119, 6.303) 0.016
Core biopsy
Tumor grade
III 2.172 (1.486, 3.176) <0.0001 1.671 (1.215, 2.829) 0.01 0.322 (0.966, 3.347) 0.075
II
I
Lymph node
N3 4.053 (2.850, 5.755) <0.0001 3.037 (1.808, 5.104) <0.0001 0.335 (1.624, 6.221) 0.001
N1 or N2
N0
ER/PR
(-, -), (-, +), (+, -) 1.99 (1.194, 3.331) 0.009 2.778 (1.231, 6.260) 0.045 0.451 (1.306, 7.996) 0.011
(+, +)
Chemotherapy
Yes (a) 2.558 (c v.s. a) (1.263, 5.155) <0.0001 4.348 (1.631,
11.494)
0.002 0.852 (1.339, 13.514) 0.003
No (b) 16.393 (c v.s.
b)
(5.051,
52.632)
12.658 (2.558, 62.5) 3.761 (18.868,
2.87*10
9)
Abandonment or
Refusal (c)
Table 3 Description of the population by univariate logis-
tic regression test using the pathological data (Continued)
No (a) (n = 327) 4 (1.2%)
Yes (b) (n = 745) 55 (7.4%)
Abandonment or Refusal (c)
(n = 65)
11 (18%)
N. S.: Statistically not significant
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however, this system is based solely on disease-related
parameters and does not include diverse variables,
including diagnostic methods, which may influence the
outcome of patients. Furthermore, a comprehensive pre-
dictive model should also take into account treatment
modalities, including chemotherapy, hormone therapy
or targeted therapy, which are currently either in use or
are under study [21-23].
The impact of the race of the individual on the survi-
val of breast cancer patients has been reported [24-26].
To our knowledge, the current study is the first to
demonstrate systematically the influence of prognostic
factors on the survival of patients with breast cancer in
Asian and Pacific Islander populations. Admittedly, the
design of the model and the selection of variables
should have considerable clinical applicability. The main
purpose of our study was to construct a suitable survi-
val prediction formula for Taiwanese women. To create
a survival prediction model for breast cancer, we used a
comprehensive dataset that included clinico-pathological
data, diagnostic modalities, and treatment variables
from Taiwanese patients who suffering from this
disease.
Our model building exercise showed that age, ultra-
sound diagnostic classification, mammography diagnos-
tic classification, diagnosis by core biopsy, tumor grade,
ER/PR status, lymph node status, and chemotherapy are
the most important predictive factors for breast cancer
in Taiwanese women. The combination of these risk fac-
tors using multivariable logistic regression analysis, led
to the development of a predictive formula for breast
cancer survival. Our data also draw attention to the
importance and influence of diagnostic modalities on
breast cancer survival rate. In our model building exer-
cise, the use of ultrasound, mammography, and core
biopsy technologies had a high impact on disease
outcome.
T h ep r o g n o s t i cp o w e ri nad i s e a s ec o n t e x tc a nb e
improved by applying a predictive model, even when
using TNM data or other predictive factors [7,22,27].
Burke et al. [28] demonstrated that the predictive accu-
racy for breast and colon carcinoma could be improved
by using an ANN-based model using TNM information
exclusively. Similarly, in the current study we created an
additional model for the prediction of survival in
patients with breast cancer using data that was more
complete than TNM staging information.
The high predictive accuracy of the current model
may stem from several factors. First, in other models,
investigators often relied strongly on input data that
were weighted toward tumor histopathological para-
meters, rather than toward clinical or demographic
patient data [6,17,19,21,27]. This is in contrast to the
current model, in which several parameters, including
diagnostic and treatment modalities or demographic
data, represented the majority of the selected optimal
variable datasets. Second, the current study is the first
to use prognostic factors as a predictive tool in Asian
breast cancer populations.
Caution should nevertheless be employed when gen-
erating and interpreting data using our model building
exercise. First, the current model was based on data
Figure 2 ROC curve calculated by the multiple logistic
regression model.
Figure 3 The curve of the predicted and observed probability
of death.
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of this model should be verified before its application
to patients from other populations or institutions. The
variability in survival rates observed for breast cancer
patients from different countries seems to support this
argument [25,26]. A possible method for overcoming
this limitation may be the inclusion of patients from
other Asian populations in the construction of a new
model. Thus, the identification and evaluation of uni-
versally applicable variables may require collaborations
between different institutions or nations. Nevertheless,
the current pilot study serves as a proof-of-principle
strategy that underscores the utility of this model
building exercise. Second, the data used here were not
established from prospective and randomized studies.
If other users wish to adopt our model building exer-
cise for the selection of therapeutic methods, then any
variables pertaining to focused treatment methods
should be compared with standardized protocols. If
treatment variables were included, any result would be
biased by case-by-case selection criteria for that parti-
cular treatment; [7,8] therefore, a web-based predic-
tion engine may facilitate its use by clinicians in the
future.
Conclusions
We have designed an effective model for predicting out-
comes in Taiwanese breast cancer patients by combin-
ing demographic, clinical, and pathological data,
including multiple tumor-related and patient-related
variables. Our model building exercise showed a strong
potential to enhance the prediction of patient survival
and to identify important variables that have an impact
on disease outcomes. Information provided by this
model building exercise may improve the selection of
appropriate and effective therapy for breast cancer
patients.
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